Sectors

  • Biotech
  • Digital Health 
  • Healthcare
  • Medical Technology
  • Service & Technology
  • Special Industrial Machinery
  • Strategy 

Research Coverage

  • Actinium Pharmaceuticals, Inc. (ATNM)
  • Energy Fuels Inc. (UUUU)
  • Hyperfine, Inc. (HYPR)
  • Mirion Technologies, Inc. (MIR)
  • Radiopharm Theranostics Ltd. (RADX-US)
  • RadNet, Inc. (RDNT)
  • Tango Therapeutics, Inc. (TNGX)
  • The Oncology Institute, Inc. (TOI)

Affiliations

  • American Association for Cancer Research
  • Society for Immunotherapy of Cancer
  • American Society of Clinical Oncology
  • Cancer Prevention and Research Institute of Texas

Biography 

Yuan Zhi, Ph.D., is a senior healthcare equity research analyst at B. Riley Securities. He joined the healthcare research team in 2020 to focus on the coverage of smid-cap biotech companies developing cutting-edge therapeutics. His research coverage focuses on the value chain of radiopharmaceuticals and oncology care. Dr. Zhi also serves as a product development peer reviewer at the Cancer Prevention and Research Institute of Texas. Before joining B. Riley, he was with Sirona Capital, a family office focusing on biotech investment. Prior to Sirona Capital, he was trained through an R&D internship at Elanco, developing vaccines and biologics; the Regulatory Affairs Training Program at Duke University School of Medicine; and Quantitative Sciences in Drug Development at Novartis.

Dr. Zhi received a B.Sc. in chemistry from Wuhan University and a Ph.D. in biochemistry from Texas A&M University. He passed the CFA level II exam in 2018.